Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class Of Early Cancer Detection Test

15 Jan 2021

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.

Baltimore-based liquid biopsy start-up Delfi Diagnostics raised $100m in a series A round led by OrbiMed Advisors LLC, the company announced 12 January.

Delfi plans to use the funds to expand its team of cancer researchers and machine-learning experts and to validate its...